Shares of AstraZeneca dipped on Friday after U.S. regulators recommended against its new cancer drug. The FDA advisory committee voted 6-3 against approving camizestrant, an oral medication aimed at treating a specific type of breast cancer. The panel raised concerns about the trial’s design and its effectiveness in improving long-term survival.
Typically, the FDA listens to its advisory panels but is not obligated to follow their recommendations. AstraZeneca’s shares slipped about 2% in morning trading. Those who voted against camizestrant felt the trial did not convincingly show that switching to this treatment improved patient outcomes compared to current therapies.
The drug aimed to address hormone receptor-positive breast cancer, and the trial results indicated a 56% reduction in the risk of disease progression or death when compared to standard treatments. Despite the setback, Barclays analyst James Gordon noted that the committee did not entirely dismiss the drug’s potential. They simply believed the evidence didn’t strongly support changing therapies early on.
Interestingly, safety concerns around camizestrant were minimal. Instead, analysts warned that pushing for an earlier treatment switch could introduce risks, potentially limiting time with effective options.
AstraZeneca remains optimistic. Susan Galbraith, the Executive Vice President of Oncology, stated the company will continue working with the FDA to pursue approval. Jefferies analysts pointed out that while this news might affect sentiment, it wouldn’t derail AstraZeneca’s broader goals. The company is still targeting $80 billion in sales by 2030, with a string of promising developments on the horizon.
In the past year, AstraZeneca shares gained about 25%, significantly outperforming the FTSE 100 index’s 20% rise. The company is focusing on growth and innovation, with 11 more data readouts expected in 2026. Recently it also surpassed sales and profit expectations in its first-quarter results, keeping it on track for its mid-term objectives.
For a more comprehensive look at the ongoing developments in AstraZeneca’s approvals and market performance, check the detailed report on the FDA’s advisory panel’s review here.
Source link
AstraZeneca PLC,FTSE 100,Pharmaceuticals,Biotech and Pharmaceuticals,Business,United States,business news
